Healthy male and female subjects.
Conditions
Interventions
Each ml suspention contians 6 mg of Oseltamivir,Each ml suspention contians 6 mg of Oseltamivir
Experimental Drug,Experimental Drug
GPO-
FLU (Oseltamivir 6 mg/ml powder for oral suspension) ,Tamiflu (Oseltamivir 6 mg/ml powder for oral suspension)
Sponsors
The Government Pharmaceutical Organization
Eligibility
Sex/Gender
All
Age
0 Years to 0 Years
Inclusion criteria
Inclusion criteria: i. Non hormonal intrauterine device in place of at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, such as condoms, foams, jellies, diaphragm, etc., or iii. Surgery sterilization or iv. Practicing sexual abstinence throughout the course of the study. OR -Females were not considered of childbearing potential if one of the following was reported and documented on the medical history: i. Postmenopausal with spontaneous amenorrhea for at least one year, or ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iii. Total hysterectomy and absence of bleeding for at least 3 month. AND - Females demonstrate a negative pregnancy test performed at screening. - Females without currently breast-feeding.
Exclusion criteria
Exclusion criteria: a) Any history of hypersensitivity to oseltamivir or any component of the product. b) A recent history or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system. c) Clinically significant illness within 4 weeks before the start of the study. d) Any history of bronchospasm, asthma, urticaria or other allergic type reactions after taking any medication. e) A positive hepatitis screen including HBsAg and/or anti-HCV. f) A positive test result for anti-HIV. g) Has participated in any other clinical trial involving drug administration and collection of blood samples or has donated blood (1 unit or 350 mL) in the preceding 90 days prior to the start of the study. h) History of difficulty with donating blood or difficulty in accessibility of veins. i) A recent history of harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc), or consumption of alcohol or alcoholic product within 48 hours prior to dosing, or testing positive in pre-study breath test for alcohol consumption. j) Consumption of grapefruit, pomelo, orange, or any products containing these fruits within 48 hours prior to dosing. k) Consumption of xanthine containing products (i.e. tea, coffee, chocolates or cola drinks) more than 3 cups/day or consuming these products within 24 hours prior to dosing. l) Heavy smoking ( 10 cigarettes/day) m) Moderate smoking (< 10 cigarettes/day) and consumption of tobacco containing products, which cannot stop smoking or consuming 24 hours prior to dosing and for entire duration of the study. n) Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans. o) Consumption of any medication (including over-the-counter products, herbal remedies), or vitamins, or dietary supplements at any time within 14 days prior to dosing. In any such case subject selection will be at the discretion of the Principal Investigator. p) Any food allergy, intolerance, restriction or special diet that, in the opinion of Principal Investigator, could contraindicate the volunteer’s participation in the study. q) Difficulty in swallowing solids dosage forms like tablets or capsules. r) Intolerance to venipuncture.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90%CI of pharmacokinetic parameters derived from drug plasma concentration-time profile Pre-dose and at 1, 2, 4, 8, 12, and 24 hrs post-dose Bioanalysis and pharmacokinetic data analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events/Severe adverse events Pre-dose and at 1, 2, 4, 8, 12, and 24 hrs post-dose Physical and biochemical examination eg. vital signs; blood pressure, pulse rate | — |
Countries
Thailand
Contacts
Public ContactPorranee Puranajoti
International Bio Service Co., Ltd.
Outcome results
None listed